U.S. markets open in 3 hours 49 minutes
  • S&P Futures

    4,363.50
    +20.25 (+0.47%)
     
  • Dow Futures

    33,960.00
    +162.00 (+0.48%)
     
  • Nasdaq Futures

    15,070.00
    +46.00 (+0.31%)
     
  • Russell 2000 Futures

    2,195.30
    +14.40 (+0.66%)
     
  • Crude Oil

    71.60
    +1.11 (+1.57%)
     
  • Gold

    1,776.10
    -2.10 (-0.12%)
     
  • Silver

    22.53
    -0.04 (-0.17%)
     
  • EUR/USD

    1.1738
    +0.0008 (+0.07%)
     
  • 10-Yr Bond

    1.3240
    0.0000 (0.00%)
     
  • Vix

    22.84
    -2.87 (-11.16%)
     
  • GBP/USD

    1.3636
    -0.0028 (-0.21%)
     
  • USD/JPY

    109.4930
    +0.2730 (+0.25%)
     
  • BTC-USD

    42,433.91
    -832.46 (-1.92%)
     
  • CMC Crypto 200

    1,058.14
    -5.70 (-0.54%)
     
  • FTSE 100

    7,058.38
    +77.40 (+1.11%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Cyteir Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

LEXINGTON, Mass., August 02, 2021--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that its President and Chief Executive Officer Markus Renschler, MD will participate in the 2021 Wedbush PacGrow Healthcare Conference, being held virtually on August 10, 2021.

12th Annual Wedbush PacGrow Healthcare Virtual Conference

Date: Tuesday, August 10

Time: 11:30 AM EDT

Panel: Synthetic Lethal (Weapon)

A live webcast of the Wedbush panel discussion will be available in the Investors & Media section of the Cyteir website at www.cyteir.com. A webcast replay will also be available on the website shortly after conclusion of the event for 30 days.

About Cyteir Therapeutics, Inc.

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210802005046/en/

Contacts

INVESTOR CONTACT:
Lisa Hayes
Vice President, Investor Relations and Corporate Communications
908-868-8926
Lisa.Hayes@cyteir.com

MEDIA CONTACT:
Michele Parisi
925-429-1850
mparisi@forwardhealthinc.com